Fungal Infections in Severe COVID-19 Patients
Author Information
Author(s): Maeshima Katsuya, Yamamoto Ryo, Matsumura Kazuki, Kaito Daiki, Homma Koichiro, Yamakawa Kazuma, Tagami Takashi, Hayakawa Mineji, Ogura Takayuki, Hirayama Atsushi, Yasunaga Hideo, Sasaki Junichi
Primary Institution: Keio University School of Medicine
Hypothesis
What clinical factors are associated with fungal infections during severe COVID-19 treatment?
Conclusion
In patients with severe COVID-19 requiring mechanical ventilation, each additional day of steroid use was linked to longer antifungal medication use.
Supporting Evidence
- Fungal infections occurred in 57 out of 559 patients (10.2%).
- Duration of steroid use was significantly associated with fungal infections.
- Patients with fungal infections had higher in-hospital mortality rates.
- Patients with fungal infections had longer hospital stays compared to those without.
- Each additional day of steroid use increased the risk of fungal infection.
Takeaway
The longer patients with severe COVID-19 take steroids, the more likely they are to need antifungal medicine.
Methodology
This was a post hoc analysis of the J-RECOVER study, a multicenter retrospective observational study involving patients with COVID-19 who required admission at 66 hospitals.
Potential Biases
Potential biases due to unmeasured confounding factors such as liver disease and malignancies.
Limitations
The study's retrospective design may have introduced biases due to unmeasured confounding factors, and microbiological data for fungal infections were lacking.
Participant Demographics
The median age of participants was 72 years for those with fungal infections and 66 years for those without.
Statistical Information
P-Value
<0.001
Confidence Interval
1.00–1.01
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website